Global Atomic Corp. , announced today its operating and financial results for the year ended 31, 2024. For more detail, please refer to the Consolidated Financial Statements and Management's ...
FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome New data, including lacutamab improved health-related quality of life data from TELLOMAK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback